Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells.

@article{Kamigaki2011StatinsIA,
  title={Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells.},
  author={Michihiro Kamigaki and Tamito Sasaki and Masahiro Serikawa and Motoki Inoue and Kenso Kobayashi and Hiroshi Itsuki and Tomoyuki Minami and Masanobu Yukutake and Akihito Okazaki and Takashi Ishigaki and Yasutaka Ishii and Keiichi Kosaka and Kazuaki Chayama},
  journal={International journal of oncology},
  year={2011},
  volume={39 3},
  pages={
          561-8
        },
  url={https://api.semanticscholar.org/CorpusID:25259294}
}
Treatment of human cholangiocarcinoma cells with statins induced apoptosis via suppression of the classical MAPK pathway, suggesting that statins may be a new cholangsiocARCinoma treatment option that could potentially enhance the anticancer effect of pre-existing anticancer drugs.
View on PubMed
spandidos-publications.com
44 Citations
Highly Influential Citations
1
Background Citations
16

Figures and Tables from this paper

44 Citations

Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells.

Effects of Simvastatin in Combination with Anticancer Drugs on Proliferation and Migration in Cholangiocarcinoma Cells

The combination of simvastatin with anticancer drugs could be considered a novel strategy to expand treatment options for cholangiocarcinoma.

Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells

Results indicate that gemcitabine plus atorvastatin could serve as a potential novel treatment option for CCA and the anti-cancer effects of the individual agents were significantly enhanced in combination.

Lovastatin inhibits human B lymphoma cell proliferation by reducing intracellular ROS and TRPC6 expression.

Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells.

Simvastatin acts synergistically with the anticancer drug doxorubicin against MCF-7 cells, possibly through a downregulation of the cell cycle or induction of apoptosis.

Simvastatin Induces Apoptosis and Suppresses Insulin-Like Growth Factor 1 Receptor in Bile Duct Cancer Cells

Simvastatin induces apoptosis in biles duct cancer cells, which suggests that it could be an antineoplastic agent for bile duct cancer.

Pitavastatin Is a Highly Potent Inhibitor of T-Cell Proliferation

The results suggest that Pitavastatin is a highly potent inhibitor of T-cell proliferation, which induces apoptosis via pro-apoptotic ERK1/2 activation, thus representing a potential repositioning candidate for the treatment of T -cell-mediated autoimmune diseases.

Inhibition of growth and migration of cholangiocarcinoma cells by pamidronate

Pamidronate significantly decreased the protein expression levels of Rac1 in the MVA signaling pathway and may therefore be beneficial for developing a novel chemotherapeutic method for CCA.

Effects of statins on brain tumors: a review.

Pitavastatin suppressed liver cancer cells in vitro and in vivo

The antiliver cancer effect of the old drug pitavastatin may be developed as a drug for liver cancer therapy and reversed the cleavage of cytotoxic effect of pitvastatin.

39 References

Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells.

Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase

The statins as anticancer agents.

Potential future directions in the development of the statins as anticancer agents include combinations with chemotherapeutic or other molecular-targeted agents, combinations with radiotherapy, maintenance therapy in minimal disease status, and as chemopreventive therapy.

Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo.

The combination of statins and pamidronate, a second generation bisphosphonate, demonstrates promising antitumor effects at doses readily achievable in patients, and holds promise for future clinical studies.

Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma

It is shown that of a panel of 17 genetically distinct MM cell lines, half were sensitive to statin-induced apoptosis and, despite pharmacodynamic evidence of drug uptake and activity, the remainder were insensitive, suggesting that statins may be a useful molecular targeted therapy in the treatment of a subset of MM.

Breast cancer growth prevention by statins.

In vivo results showed that oral dosing of statins significantly inhibited the growth of a mouse mammary carcinoma, and supporting rationale for future statin trials in breast cancer patients is provided.

Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.

It is demonstrated that the apoptotic properties of lovastatin are triggered by the open ring acid form that is a potent inhibitor of HMG-CoA reductase activity.

Mutual amplification of apoptosis by statin‐induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells

It is shown that statins activate the mitochondrial pathway of apoptosis in rhabdomyosarcoma RD cells via translocation of Bax from the cytosol to mitochondria and the presence of doxorubicin increased the potency of simvastatin to trigger caspase activation, indicating that deprivation of cholesterol precursors is essential for statin‐induced apoptosis.

Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.

Cerivastatin potentiated cytostatic/cytotoxic effects of cisplatin against T4-2 cells and those of doxorubicin against both cell lines and these studies indicate that cervastatin is another HMG-CoA reductase inhibitor with potent antitumor effects.

Induction of apoptosis by ionizing radiation and CI-1033 in HuCCT-1 cells.